Premium
Impact of cord blood banking technologies on clinical outcome: a Eurocord/Cord Blood Committee (CTIWP), European Society for Blood and Marrow Transplantation and NetCord retrospective analysis
Author(s) -
Saccardi Riccardo,
Tucunduva Luciana,
Ruggeri Annalisa,
Ionescu Irina,
Koegler Gesine,
Querol Sergio,
Grazzini Giuliano,
Lecchi Lucilla,
Nanni Costa Alessandro,
Navarrete Cristina,
Pouthiers Fabienne,
Larghero Jerome,
Regan Donna,
Freeman Taryn,
Bittencourt Henrique,
Kenzey Chantal,
Labopin Myriam,
Baudoux Etienne,
Rocha Vanderson,
Gluckman Eliane
Publication year - 2016
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/trf.13661
Subject(s) - cord blood , medicine , transplantation , cumulative incidence , hematopoietic stem cell transplantation , surgery , oncology
BACKGROUND Techniques for banking cord blood units (CBUs) as source for hematopoietic stem cell transplantation have been developed over the past 20 years, aimed to improve laboratory efficiency without altering the biologic properties of the graft. A large‐scale, registry‐based assessment of the impact of the banking variables on the clinical outcome is currently missing. STUDY DESIGN AND METHODS A total of 677 single cord blood transplants (CBTs) carried out for acute leukemia in complete remission in centers affiliated with the European Society for Blood and Marrow Transplantation were selected. An extensive set of data concerning CBU banking were collected and correlations with clinical outcome were assessed. Clinical endpoints were transplant‐related mortality, engraftment, and graft‐versus‐host disease (GVHD). RESULTS The median time between collection and CBT was 4.1 years (range, 0.2‐16.3 years). Volume reduction (VR) of CBUs before freezing was performed in 59.2% of available reports; in half of these the frozen volume was less than 30 mL. Cumulative incidences of neutrophil engraftment on Day 60, 100‐day acute GVHD (II‐IV), and 4‐year chronic GVHD were 87, 29, and 21 ± 2%. The cumulative incidence of nonrelapse mortality (NRM) at 100 days and 4‐year NRM were, respectively, 16 ± 2 and 30 ± 2%. Neither the variables related to banking procedures nor the interval between collection and CBT influenced the clinical outcome. CONCLUSION These findings indicate a satisfactory validation of the techniques associated with CBU VR across the banks. Cell viability assessment varied among the banks, suggesting that efforts to improve the standardization of CBU quality controls are needed.